Mylan NV operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Mylan NV with three other
companies in this sector in the United States:
Daiichi Sankyo Company Limited
(2018
sales of $8.68 billion
of which 92%
was Prescription drugs),
Celgene Corporation
($15.28 billion
of which 100%
was Biopharmaceuticals), and
CSL Limited
($7.92 billion
of which 84%
was CSL Behring).
Sales Analysis.
Mylan NV reported sales of $11.43 billion
for the
year ending
December of 2018.
This
represents
a
decrease of 4.0%
versus 2017, when the company's sales were $11.91 billion.
Contributing to the drop in overall sales was the 16.8% decline
in North America, from $5.06 billion to $4.21 billion.
.
However, these declines were partially offset by the increase in sales of
Europe (up 4.7% to $4.18 billion)
and
Rest of World (up 6.5% to $3.04 billion)
.